Imagine being told there's a life-changing treatment for a condition affecting millions, only to find out it's out of reach for most who need it. That's the reality for many in Southend, where the Mounjaro weight loss jab, a groundbreaking obesity treatment, is leaving residents feeling 'left behind'. But here's where it gets controversial... While nationally around 3.4 million people meet the eligibility criteria, the NHS plans to treat a mere 220,000 over three years. That's less than 7% of those who could benefit. To incentivize prescriptions, GP surgeries are set to receive a £3,000 bonus for each patient they put on the drug. Sounds fair, right? Not quite. A typical GP practice with 6,000 patients might have fewer than 20 eligible individuals, yet the first year's funding is expected to cover only a fraction of that number. And this is the part most people miss... The Lib Dems highlight that Southend faces some of the most glaring health inequalities in the UK, with a staggering 10.5-year gap in male life expectancy between the wealthiest and poorest areas. Obesity, a key driver of this disparity, is often tied to socioeconomic factors, yet the Mounjaro jab, costing £160 to £310 per month privately, remains unaffordable for many. This raises a critical question: Is the NHS doing enough to address health inequalities, or are we perpetuating a system where only the privileged can access life-altering treatments? What do you think? Share your thoughts in the comments—let’s spark a conversation about fairness in healthcare.
